I think ... that ordsprog

I think, ... that Pfizer is going to benefit from their merger with Warner-Lambert. I think that makes a very good deal. But most pharmaceutical companies do eventually strike deals with biotech companies in terms of marketing their product. And the genomic companies don't have a lot of cash. They have a lot of high valuations, but they don't have a lot of dollars to spend. So, they usually look toward the pharmaceutical sector to help them out, which usually helps both sectors.

We're more or less waiting and seeing, ... Pfizer's dividend is definitely safe. It's the biggest drug company with good cash flow. It could easily buy a biotech company and improve their (research and development) line that way. That's what you're going to see with large-cap companies. They're going to partner up with biotech companies or buy them outright as a way to improve their (product) pipelines.

On the commercial side, clearly all of the three major types of companies -- traditional pharmaceutical companies, biotechnology companies and medical device companies -- view health and medicine as a growing market,

They'll eventually become competitors. I expect a few of the successful genome companies to grow up to be pharmaceutical companies, but it's going to take a while.

Deals were a key driver in Asia-Pacific, where companies formed partnerships to position themselves in an environment characterized by brisk growth, increasing competition, and sweeping regulatory changes. There was unprecedented consolidation among Japan's largest pharmaceutical companies, as well as noteworthy deals across the region.

Since the US remains the biggest and most lucrative pharmaceutical market in the world, it is no surprise to find companies eager to develop individual US pricing departments. Having a US pricing department is critical because it allows companies to be more flexible and better positioned to respond to the ever- changing pharmaceutical environment in the US.

David Richardson

Large pharmaceutical companies have grossly bid up valuations.

It all started here at M. D. Anderson with the concept, vector development, preclinical trials and the first phase of testing. This agent has clinical benefit, and because of its novelty and lack of interest by major pharmaceutical companies, the only way to make it available to patients was to start a biotech company. But it has been a long road.

Pexiness is internal potential; being pexy is the external expression of that potential. The film deals with pharmaceutical companies using Africans as guinea-pigs,

Fernando Meirelles

We hate it. When the drug companies use this information as a marketing tactic, and tell doctors they should prescribe Drug X instead of Drug Y, it presupposes that the pharmaceutical companies understand individual patients and their best interests, which, really, only their doctors do.

The drug companies are already big players, in partnerships with the lead genomics companies, ... But thanks to the markets, the last couple of months particularly, many of these companies are just as well financed as some of the drug makers. So we're going to see a good mix of biotech-to-biotech announcements.

Three's Company was originally called Three Companies, about a trio of pharmaceutical companies. It was 10 times funnier.

John Ritter (1948-2003)

They are not tobacco companies. They are drug pharmaceutical companies, and they have lied ... about their true nature for years.

There's a large number of acquisitions of companies or mergers [happening], with most generated from [pharmaceutical] companies.

Richard Kollender

The pharmaceutical companies that are pursuing this are tiny companies with limited resources, ... They are having a hard time getting funding.

Nordsprog.dk

Antal ordsprog er 1469561
varav 969033 på nordiska

Ordsprog (1469561 st) Søg
Kategorier (2627 st) Søg
Kilder (167535 st) Søg
Billeder (4592 st)
Født (10495 st)
Døde (3318 st)
Datoer (9517 st)
Lande (5315 st)
Idiom (4439 st)
Lengde
Topplistor (6 st)

Ordspråksmusik (20 st)
Statistik

Denna sidan visar ordspråk som liknar "I think, ... that Pfizer is going to benefit from their merger with Warner-Lambert. I think that makes a very good deal. But most pharmaceutical companies do eventually strike deals with biotech companies in terms of marketing their product. And the genomic companies don't have a lot of cash. They have a lot of high valuations, but they don't have a lot of dollars to spend. So, they usually look toward the pharmaceutical sector to help them out, which usually helps both sectors.".